MLTX LEGAL ALERT: MoonLake Immunotherapeutics Hit with Securities Fraud Class Action due to Drug Trial Results -- Investors Notified to Contact BFA Law by December 15

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, particularly through its investigational therapeutic sonelokimab [3]. Clinical Trials and Data - The company conducted Phase 3 VELA trials for sonelokimab, which were highly anticipated, and claimed that its "strong clinical data" would lead to higher clinical responses compared to competitors [3][4]. - MoonLake asserted that the Nanobody structure of sonelokimab provided beneficial differences over traditional monoclonal antibody treatments [4]. Allegations and Stock Impact - Allegations state that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [5]. - Following the announcement of disappointing results from the VELA trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [6].